TRACON Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de TRACON Pharmaceuticals de 53.5% y 58.7% respectivamente, mientras que el BPA crecerá en un 54.3% al año.

Información clave

53.5%

Tasa de crecimiento de los beneficios

54.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	21.3%
Tasa de crecimiento de los ingresos	58.7%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	10 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Tracon Pharmaceuticals announces $35M non-dilutive debt facility

Sep 06

Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma

Aug 29

Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study

Dec 10

Tracon Pharma files China application for envafolimab in solid tumors

Nov 16

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:TCON - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	32	-4	N/A	4	2
12/31/2025	N/A	-21	N/A	-13	2
12/31/2024	N/A	-16	N/A	-7	2
12/31/2023	12	-4	4	4	N/A
9/30/2023	9	-11	0	0	N/A
6/30/2023	9	-28	-22	-22	N/A
3/31/2023	N/A	-28	-25	-24	N/A
12/31/2022	N/A	-29	-26	-26	N/A
9/30/2022	N/A	-30	-27	-27	N/A
6/30/2022	N/A	-30	-28	-28	N/A
3/31/2022	0	-33	-25	-24	N/A
12/31/2021	0	-29	-23	-23	N/A
9/30/2021	0	-25	-21	-21	N/A
6/30/2021	0	-22	-17	-17	N/A
3/31/2021	N/A	-18	-17	-17	N/A
12/31/2020	N/A	-17	-17	-17	N/A
9/30/2020	N/A	-16	-18	-18	N/A
6/30/2020	N/A	-18	-20	-20	N/A
3/31/2020	N/A	-19	-22	-22	N/A
12/31/2019	N/A	-23	-24	-24	N/A
9/30/2019	N/A	-26	-28	-28	N/A
6/30/2019	N/A	-30	-27	-27	N/A
3/31/2019	N/A	-34	-32	-32	N/A
12/31/2018	3	-35	-31	-31	N/A
9/30/2018	3	-34	-25	-25	N/A
6/30/2018	10	-24	-17	-17	N/A
3/31/2018	11	-20	-12	-12	N/A
12/31/2017	9	-19	-13	-13	N/A
9/30/2017	9	-19	N/A	-17	N/A
6/30/2017	3	-26	N/A	-23	N/A
3/31/2017	3	-28	N/A	-28	N/A
12/31/2016	3	-27	N/A	-27	N/A
9/30/2016	4	-32	N/A	-29	N/A
6/30/2016	5	-32	N/A	-27	N/A
3/31/2016	8	-27	N/A	-21	N/A
12/31/2015	8	-24	N/A	-19	N/A
9/30/2015	8	-16	N/A	-15	N/A
6/30/2015	8	-12	N/A	-13	N/A
3/31/2015	4	-10	N/A	-11	N/A
12/31/2014	4	-7	N/A	2	N/A
9/30/2014	3	-7	N/A	3	N/A
6/30/2014	1	-7	N/A	3	N/A
3/31/2014	0	-8	N/A	3	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que TCON siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que TCON siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que TCON siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que TCON no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que TCON no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de TCON se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

TRACON Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates upgraded to US$0.45 loss

Consensus revenue estimates increase by 50%

Consensus revenue estimates increase by 100%

Price target decreased by 21% to US$7.33

Price target decreased by 12% to US$9.33

No longer forecast to breakeven

Recent updates

TRACON Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

TRACON Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned

Insufficient new directors

New major risk - Share price stability

New major risk - Shareholder dilution

TRACON Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

TRACON Pharmaceuticals, Inc. Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial

Consensus EPS estimates upgraded to US$0.45 loss

TRACON Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

New major risk - Revenue and earnings growth

New major risk - Share price stability

TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned

New major risk - Financial position

Consensus revenue estimates increase by 50%

TRACON Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023

TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial

TRACON Pharmaceuticals Receives Notice from Nasdaq Regarding Non-Compliance with the Market Value Rule and Minimum Bid Price Requirement

Consensus revenue estimates increase by 100%

Price target decreased by 21% to US$7.33

TRACON Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 10, 2023

Price target decreased by 12% to US$9.33

No longer forecast to breakeven

TRACON Pharmaceuticals Receives A Letter from Nasdaq Regarding Market Value Rule

TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial

TRACON Pharmaceuticals, Inc Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma

Price target decreased to US$10.20

TRACON Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

TRACON Pharmaceuticals, Inc. Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from Envasarc Phase 2 Pivotal Trial

TRACON Pharmaceuticals Announces Fast Track Designation by the Food and Drug Administration for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS

Tracon Pharmaceuticals announces $35M non-dilutive debt facility

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. and TRACON Pharmaceuticals, Inc. Announce U.S. Food and Drug Administration Approval of Investigational New Drug

Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma

Consensus forecasts updated

TRACON Pharmaceuticals, Inc. Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial

Tracon GAAP EPS of -$0.31 beats by $0.05, revenue of $0M

TRACON Pharmaceuticals, Inc. Submits IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-Line Sarcoma Patients in Combination with Envafolimab

TRACON Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 10, 2022

TRACON Pharmaceuticals Announces Dosing of 36Th Patient in Envasarc Pivotal Trial Triggering Initial Idmc Efficacy Review Expected in the Fourth Quarter

Consensus revenue estimates increase by 99%

TRACON Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 11, 2022

TRACON Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Forecast to breakeven in 2024

TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K

No longer forecast to breakeven

No longer forecast to breakeven

TRACON Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 15, 2022

TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer Institute

TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial

TRACON Pharmaceuticals, Inc. Reports Regulatory Approval of Envafolimab in China

TRACON Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting

TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial

TRACON Pharmaceuticals, Inc. Announces Appointment of Lisa Johnson-Pratt to its Board of Directors

TRACON Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $8.805977 million.

TRACON Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Tracon Pharmaceuticals, Inc. Announces Executive Changes

TRACON Pharmaceuticals announces $5M registered direct offering

TRACON Pharma launches $8.8M direct offering

TRACON Pharmaceuticals, Inc. Announces Dosing of First Patient in ENVASARC Pivotal Trial

Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study

TRACON Pharmaceuticals, Inc. Announces Publication in Cancer Cell of Clinical Data That Provides Molecular Insight into the Mechanism of Action of Trc102 and Patient Populations Most Likely to Respond to Treatment

TRACON Pharmaceuticals Announces Submission for Approval of Envafolimab (KN035) with the NMPA in China by its Corporate Partners Alphamab Oncology and 3D Medicines

Tracon Pharma files China application for envafolimab in solid tumors

TRACON Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Tracon Pharmaceuticals Highlights Updated Envafolimab Clinical Results in MSI-H/dMMR Colorectal Cancer

TRACON Pharmaceuticals, Inc. announced that it expects to receive $4.999998 million in funding from Opaleye Management Inc.

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas